Trimethoprim-sulfamethoxazole
JD Smilack - Mayo Clinic Proceedings, 1999 - Elsevier
After 25 years of use in the United States, trimethoprimsulfamethoxazole (TMP-SMX) is
widely prescribed for various indications. By virtue of sequential blockade of microbial folic …
widely prescribed for various indications. By virtue of sequential blockade of microbial folic …
Pneumocystis jirovecii pneumonia in people living with HIV: a review
EG McDonald, A Afshar, B Assiri, T Boyles… - Clinical Microbiology …, 2024 - Am Soc Microbiol
Pneumocystis jirovecii is a ubiquitous opportunistic fungus that can cause life-threatening
pneumonia. People with HIV (PWH) who have low CD4 counts are one of the populations at …
pneumonia. People with HIV (PWH) who have low CD4 counts are one of the populations at …
Diagnostic performance of metagenomic next-generation sequencing for Pneumocystis jirovecii pneumonia
X Li, Z Li, J Ye, W Ye - BMC Infectious Diseases, 2023 - Springer
Objective Pneumocystis jirovecii pneumonia (PJP) can be a life-threatening opportunistic
infection. We aimed to evaluate the diagnostic accuracy of metagenomic next-generation …
infection. We aimed to evaluate the diagnostic accuracy of metagenomic next-generation …
Detection of Pneumocystis and Morphological Description of Fungal Distribution and Severity of Infection in Thirty-Six Mammal Species
Pneumocystis spp. are thought to adapt to the lungs of potentially all mammals. However,
the full host range, fungal burden and severity of infection are unknown for many species. In …
the full host range, fungal burden and severity of infection are unknown for many species. In …
Global prevalence, mortality, and main characteristics of HIV-associated pneumocystosis: A systematic review and meta-analysis
E Ahmadpour, S Valilou, MA Ghanizadegan, R Seyfi… - Plos one, 2024 - journals.plos.org
The epidemiology of Human Immunodeficiency Virus (HIV)-associated pneumocystosis
(HAP) is poorly described on a worldwide scale. We searched related databases between …
(HAP) is poorly described on a worldwide scale. We searched related databases between …
A machine learning diagnostic model for Pneumocystis jirovecii pneumonia in patients with severe pneumonia
X Li, X Xiong, Z Liang, Y Tang - Internal and Emergency Medicine, 2023 - Springer
Abstract Background The diagnosis of Pneumocystis jirovecii pneumonia (PCP) in patients
presenting with severe pneumonia is challenging and delays in treatment were associated …
presenting with severe pneumonia is challenging and delays in treatment were associated …
Low-dose vs conventional-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in patients not infected with HIV: a multicenter, retrospective …
T Nagai, H Matsui, H Fujioka, Y Homma, A Otsuki, H Ito… - Chest, 2024 - Elsevier
Background Trimethoprim-sulfamethoxazole (TMP-SMX) is an effective treatment for
Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients with and without …
Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients with and without …
Development and Validation of a Diagnostic Nomogram for Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Pneumonia Patients Undergoing Oral …
Q Lang, L Li, Y Zhang, X He, Y Liu, Z Liu… - Infection and Drug …, 2023 - Taylor & Francis
Purpose Pneumocystis jirovecii pneumonia (PJP) is an opportunistic but potentially fatal
infection with increasing prevalence in HIV-free patients. Glucocorticoid therapy is one of the …
infection with increasing prevalence in HIV-free patients. Glucocorticoid therapy is one of the …
Pathophysiological mechanism of non-HIV Pneumocystis jirovecii pneumonia
N Asai, S Motojima, Y Ohkuni, R Matsunuma… - Respiratory …, 2022 - Elsevier
While Pneumocystis jirovecii pneumonia (PCP) can occur in immunocompromised patients
with HIV infection, the prognosis of non-HIV PCP is still poor, showing a high mortality rate of …
with HIV infection, the prognosis of non-HIV PCP is still poor, showing a high mortality rate of …